This is a preview of subscription content, log in via an institution to check access.
Notes
PRAC = Pharmacovigilance Risk Assessment Committee
see Reactions 1750 p1; 803387663
see Reactions 1755 p7; 803396356
TNF = tumour necrosis factor
Reference
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 28-31 October 2019. Internet Document : 13 Nov 2019. Available from: URL: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-28-31-october-2019
Rights and permissions
About this article
Cite this article
PRAC completes reviews of alemtuzumab and tofacitinib. Reactions Weekly 1779, 3 (2019). https://doi.org/10.1007/s40278-019-71267-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-019-71267-z